Menssana Research is the leading developer of advanced new breath tests for detection of disease. We are now performing clinical studies with the BCA and with BreathLink (TM), mostly funded by the National Institutes of Health and BARDA, to evaluate breath testing in several diseases including lung cancer, breast cancer, heart transplant rejection, radiation exposure, and tuberculosis. The Food and Drug Administration has approved the Heartsbreath test for heart transplant rejection for clinical use. For more information, please visit menssanaresearch.com.